Biotest: Clinical Trials

12 trials sponsored by Biotest, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 terminated, 1 recruiting. 12 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 8, Terminated 3, Recruiting 1
Phase 12Completed 2

Follow Biotest: new trials by email

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Cytotect®CP - Cytomegalovirus Infections
Phase 2TerminatedUniversity Hospital, Lille22022-09-132025-09-30
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B
Phase 2TerminatedHannover Medical School132022-08-152025-09-04
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
Cytotect - Kidney Transplantation, CMV Infection
Phase 2CompletedUniversity Hospital, Bordeaux422021-11-172026-05-12
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
Trimodulin, Placebo (human albumin 1%) - Covid19
Phase 2CompletedBiotest1662020-10-062023-01-10
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
Pentaglobin®/Standard of Care - Peritonitis, Sepsis
Phase 2RecruitingRWTH Aachen University2002017-11-202026-06-11
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
BT063, Placebo - Systemic Lupus Erythematosus
Phase 2CompletedBiotest362015-09-282020-01-27
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
Tregalizumab, Placebo - Rheumatoid Arthritis
Phase 2TerminatedBiotest3212013-10-012017-08-24
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
BT062 , intravenous administration - Multiple Myeloma
Phase 1 / Phase 2CompletedBiotest Pharmaceuticals Corporation642012-07-032019-07-23
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
BT086, 1% Human Albumin infusion - Community Acquired Pneumonia
Phase 2CompletedBiotest1602011-08-012015-07-29
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
BT061, Placebo - Rheumatoid Arthritis
Phase 2CompletedBiotest1272010-12-012015-02-20
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
BT062 - Multiple Myeloma
Phase 1 / Phase 2CompletedBiotest Pharmaceuticals Corporation352010-08-012019-07-30
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
BT061, placebo treatment - Psoriasis Vulgaris
Phase 2CompletedBiotest492010-02-012012-03-13

Conditions studied

Arthritis, Rheumatoid (2)  ·  Community-Acquired Pneumonia (2)  ·  Cytomegalovirus Infections (2)  ·  Multiple Myeloma (2)  ·  Autoimmune Diseases (1)  ·  COVID-19 (1)  ·  Hepatitis B, Chronic (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Peritonitis (1)  ·  Pneumonia, Bacterial (1)  ·  Recurrence (1)  ·  Respiratory Distress Syndrome (1)  ·  Sepsis (1)  ·  Shock, Septic (1)

Interventions

indatuximab ravtansine (2)  ·  Administration, Intravenous (1)  ·  cytomegalovirus-specific hyperimmune globulin (1)  ·  hepatitis B hyperimmune globulin (1)  ·  tregalizumab (1)  ·  trimodulin (1)

Countries

Germany (5)  ·  Czechia (3)  ·  France (3)  ·  Hungary (3)  ·  Poland (3)  ·  Spain (3)  ·  United States (3)  ·  Russia (2)  ·  Serbia (2)  ·  Austria (1)  ·  Belarus (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Canada (1)

Top investigators

Antoni Torres, MD (1)  ·  Gernot Marx, Univ.-Prof. (1)  ·  Heiner Wedemeyer, Prof. (1)  ·  Ibrahim Yakoub-Agha, MD,PhD (1)  ·  Kenneth C Anderson, MD (1)  ·  Kenneth C. Anderson, MD (1)  ·  Nemanja Damjanov, Professor (1)  ·  Ronald van Vollenhoven, Prof. MD (1)  ·  Tobias Welte, MD (1)

Results publications

PMID 29343509, PMID 29632995, PMID 30832742, PMID 33351126, PMID 33687069, PMID 34529955, PMID 39138518

NIH funding

2016 (1)